.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02B_VitaminKAndOtherHemostatics.B02BX07_Lusutrombopag.Lusutrombopag .Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02B_VitaminKAndOtherHemostatics.B02BX07_Lusutrombopag.Lusutrombopag| name: | Lusutrombopag | |
| ATC code: | B02BX07 | route: | oral |
| compartments: | 2 | |
| dosage: | 3 | mg |
| volume of distribution: | 105 | L |
| clearance: | 3.16 | L/h |
| other parameters in model implementation | ||
Lusutrombopag is a small-molecule thrombopoietin (TPO) receptor agonist used to treat thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. It is orally administered and stimulates platelet production by activating the TPO receptor. Lusutrombopag is approved in several countries for this indication.
Pharmacokinetics reported for adults with chronic liver disease, after oral administration of 3 mg once daily, under fasting and fed conditions.
Katsube, T, et al., & Wajima, T (2016). Population Pharmacokinetic and Pharmacodynamic Modeling of Lusutrombopag, a Newly Developed Oral Thrombopoietin Receptor Agonist, in Healthy Subjects. Clinical pharmacokinetics 55(11) 1423–1433. DOI:10.1007/s40262-016-0411-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27209291